EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Synlogic's Enterprise Value is €-9.36 Mil.
Synlogic's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-2.84 Mil. Therefore, Synlogic's EV-to-FCF for today is 3.29.
The historical rank and industry rank for Synlogic's EV-to-FCF or its related term are showing as below:
STU:MIN'
s EV-to-FCF Range Over the Past 10 Years
Min: -4.67 Med: -0.03 Max: 3.28
Current: 3.28
During the past 13 years, the highest EV-to-FCF of Synlogic was 3.28. The lowest was -4.67. And the median was -0.03.
STU:MIN's EV-to-FCF is ranked better than 68.28% of 331
companies
in the Biotechnology industry
Industry Median: 15.57
vs STU:MIN: 3.28
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Synlogic's share price for today is €3.63.
Synlogic's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.052.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Synlogic EV-to-FCF Related Terms
Synlogic EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Synlogic's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Synlogic's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synlogic EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Synlogic's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Synlogic's EV-to-FCF falls into.
Synlogic's current Enterprise Value is €-9.36 Mil.
Synlogic's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.84 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Synlogic (STU:MIN) has a EV-to-FCF of 3.29 as of Jun. 30, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Synlogic and its competitors. According to the industry distribution chart, Synlogic ranks #105 out of 331 companies in the Biotechnology industry, placing it in the top 31.7%.
Is Synlogic's EV-to-FCF too high?
Synlogic's current EV-to-FCF is 3.29. The Biotechnology industry median EV-to-FCF is 15.57. Synlogic's value of 3.29 is 78.9% below this industry median. Based on the distribution chart, Synlogic ranks #105 out of 331 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Synlogic has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Synlogic's EV-to-FCF compare to ASBP and PMCB?
According to the Biotechnology industry distribution chart, Synlogic ranks #105 out of 331 companies for EV-to-FCF. This puts Synlogic in the upper half of its industry. The industry median EV-to-FCF is 15.57. Synlogic's value of 3.29 is 78.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.57, based on 331 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Synlogic's current EV-to-FCF of 3.29 is 78.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Synlogic and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Synlogic's current EV-to-FCF is 3.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synlogic stock overvalued right now?
Synlogic (STU:MIN) has a current EV-to-FCF of 3.29. The stock's GF Value™ is €0.16, compared to a current price of €3.63 — trading 2168.8% above its estimated fair value. The current EV-to-FCF is 3.29 and 78.9% below the Biotechnology industry median of 15.57. Synlogic's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Synlogic (STU:MIN), the current EV-to-FCF is 3.29 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synlogic (STU:MIN) Overvalued in 2026?
Based on GuruFocus' analysis, Synlogic stock appears to be overvalued.
The current stock price of €3.63 is trading 2168.8% above its estimated GF Value™ of €0.16.
Key valuation signals for STU:MIN:
EV-to-FCF: 3.29
GF Value™: €0.16 vs. price of €3.63 (2168.8% above fair value)
Industry Position: 78.9% below the Biotechnology median (#105 of 331)
No single metric tells the full story. See the STU:MIN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. The pipeline drug candidates includes: labafenogene marselecobac (SYNB1934); SYNB1353 Classical Homocystinuria (HCU); SYNB8802 Enteric Hyperoxaluria; and SYNB2081 Gout. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one operating segment: Discovery and development of Synthetic Biotics.
28GF Score
Get the complete analysis for STU:MIN
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:MIN has been successfully added to your 
